Resveratrol Nanoparticles: A Promising Therapeutic Advancement over Native Resveratrol
Abstract
:1. Introduction
2. Neuroprotective Effects of Resveratrol against β-amyloid (Aβ) Administration in Rats are Improved by Lipid-Core Nanocapsules
3. RES Encapsulation in Casein Nanoparticles against Cardiac Failure Applications
3.1. Casein Nanoparticles for Oral Delivery of RES
3.2. Pharmacokinetic Superiority of Casein Nanoparticle Delivery of RES
4. Polysorbate 80-Coated Poly(lactide) Nanoparticles Loaded with RES Offers Neuroprotection in Parkinson’s Disease
5. Zein-Based Nanoparticles Improve the Oral Bioavailability of RES and Its Anti-Inflammatory Effects in a Mouse Model of Endotoxic Shock
6. Colonic-Specific Delivery of RES Using Pectin-Based Delivery Vehicles
6.1. Formulation
6.2. Shape and Size
6.3. Weight of the Microbeads
6.4. Encapsulation Efficiency
6.5. Effect of pH of the Cross-Linking Solution
6.6. Glutaraldehyde Concentration
6.7. Effect of Cross-Linking Time of the Zinc-Pectinate Beads
6.8. Pectin to RES Ratio
6.9. Swelling and Erosion of the Matrix
6.10. Cross-Linking Time
6.11. Morphology of the Zinc-Pectinate Beads and the Encapsulated RES Inside
6.12. Pharmacokinetics of Zinc-Pectinate with RES
7. Dermal Application of RES-Loaded Nanoparticles
7.1. SLN Particle Size and its Physical Properties
7.2. Effect of RES-Loaded Particles on Cell Viability—Cell Culture Studies
8. RES-Loaded Transferrin (Tf)-Modified Polyethylene Glycol-Poly Lactic Acid (PEG-PLA) Nanoparticles (Tf-PEG-PLA-RSV) in the Targeted Therapy against Glioma
9. RES-Loaded Nanoparticles in the Treatment of Cataract
10. RES-Loaded Poly (lactic-co-glycolic) acid (PLGA) Poly(-caprolactone)–poly(ethylene glycol) (PCL–PEG) Nanoparticles in Cochlear Cells
10.1. Cryoprotection and Storage
10.2. Evaluation of the Toxicity of the Nanoparticles
11. Silk Fibroin Nanoparticles Encapsulated with RES Can Fight Periodontitis
12. Protection of Cells from Oxidative Stress by RES-Loaded Polymeric Micelles
13. Effect of RES and Gold Nanoparticles on Diabetic Retinopathy
14. Mesoporous Carbon Nanoparticles and RES in the Treatment of Triple-Negative Breast Cancer
15. Solid Lipid Nanoparticles Loaded with RES in the Treatment of Colon Cancer Cells by Targeted Delivery
16. RES-Loaded Mesoporous Silica Nanoparticles for Prostate Cancer Therapy
17. RES-Co-Micellar Nanosystems in the Treatment of Arthritis
18. Treatment of Insulin Resistance in Type 2 Diabetes with Resveratrol-Loaded Solid Lipid Nanoparticles
19. Application of Resveratrol-Loaded Nanoparticles on the Wafer for Wound Healing
20. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- Sessa, M.; Tsao, R.; Liu, R.; Ferrari, G.; Donsi, F. Evaluation of the stability and antioxidant activity of nanoencapsulated resveratrol during in vitro digestion. J. Agric. Food Chem. 2011, 59, 12352–12360. [Google Scholar] [CrossRef] [PubMed]
- Amri, A.; Chaumeil, J.C.; Sfar, S.; Charrueau, C. Administration of resveratrol: What formulation solutions to bioavailability limitations? J. Control. Release 2012, 158, 182–193. [Google Scholar] [CrossRef] [PubMed]
- Granados-Soto, V. Pleiotropic effects of resveratrol. Drug News Perspect. 2003, 16, 299–307. [Google Scholar] [CrossRef] [PubMed]
- Sih, J.; Bansal, S.S.; Filippini, S.; Ferrati, S.; Raghuwansi, K.; Zabre, E.; Nicolov, E.; Fine, D.; Ferrari, M.; Palapattu, G.; et al. Characterization of nanochannel delivery membrane systems for the sustained release of resveratrol and atorvastatin: New perspectives on promoting heart health. Anal. Bioanal. Chem. 2013, 405, 1547–1557. [Google Scholar] [CrossRef]
- Baur, J.A.; Sinclair, D.A. Therapeutic potential of resveratrol: The in vivo evidence. Nat. Rev. Drug Discov. 2006, 5, 493–506. [Google Scholar] [CrossRef]
- Das, D.K.; Mukherjee, S.; Ray, D. Resveratrol and red wine, healthy heart and longevity. Heart Fail Rev. 2010, 15, 467–477. [Google Scholar] [CrossRef]
- Bradamante, S.; Barenghi, L.; Villa, A. Cardiovascular protective effects of resveratrol. Cardiovasc. Drug Rev. 2004, 22, 169–188. [Google Scholar] [CrossRef]
- Sessa, M.; Balestrieri, M.L.; Ferrari, G.; Servillo, L.; Castaldo, D.; D’Onofrio, N.; Donsi, F.; Tsao, R. Bioavailability of encapsulated resveratrol into nanoemulsion-based delivery systems. Food Chem. 2014, 147, 42–50. [Google Scholar] [CrossRef]
- Cai, B.; Zhong, T.; Chen, P.; Fu, J.; Jin, Y.; Liu, Y.; Huang, R.; Tan, L. Preparation, characterization and in vitro release study of drug-loaded sodium carboxy-methylcellulose/chitosan composite sponge. PLoS ONE 2018, 13, e0206275. [Google Scholar] [CrossRef]
- Augustin, M.A.; Sanguansri, L.; Lockett, T. Nano- and micro-encapsulated systems for enhancing the delivery of resveratrol. Ann. N. Y. Acad. Sci. 2013, 1290, 107–112. [Google Scholar] [CrossRef]
- Davidov-Pardo, G.; McClements, D.J. Nutraceutical delivery systems: Resveratrol encapsulation in grape seed oil nanoemulsions formed by spontaneous emulsification. Food Chem. 2015, 167, 205–212. [Google Scholar] [CrossRef]
- Camont, L.; Cottart, C.H.; Rhayem, Y.; Nivet-Antoine, V.; Djelidi, R.; Collin, F.; Beaudeux, J.L.; Bonnefont-Rousselot, D. Simple spectrophotometric assessment of the trans-/cis-resveratrol ratio in aqueous solutions. Anal. Chim. Acta 2009, 634, 121–128. [Google Scholar] [CrossRef] [PubMed]
- Rius, C.; Abu-Taha, M.; Hermenegildo, C.; Piqueras, L.; Cerda-Nicolas, J.M.; Issekutz, A.C.; Estan, L.; Cortijo, J.; Morcillo, E.J.; Orallo, F.; et al. Trans- but not cis-resveratrol impairs angiotensin-II-mediated vascular inflammation through inhibition of NF-kappaB activation and peroxisome proliferator-activated receptor-gamma upregulation. J. Immunol. 2010, 185, 3718–3727. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Planas, J.M.; Alfaras, I.; Colom, H.; Juan, M.E. The bioavailability and distribution of trans-resveratrol are constrained by ABC transporters. Arch. Biochem. Biophys. 2012, 527, 67–73. [Google Scholar] [CrossRef]
- Radko, Y.; Christensen, K.B.; Christensen, L.P. Semi-preparative isolation of dihydroresveratrol-3-O-beta-d-glucuronide and four resveratrol conjugates from human urine after oral intake of a resveratrol-containing dietary supplement. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2013, 930, 54–61. [Google Scholar] [CrossRef] [PubMed]
- Frozza, R.L.; Bernardi, A.; Hoppe, J.B.; Meneghetti, A.B.; Matte, A.; Battastini, A.M.; Pohlmann, A.R.; Guterres, S.S.; Salbego, C. Neuroprotective effects of resveratrol against Abeta administration in rats are improved by lipid-core nanocapsules. Mol. Neurobiol. 2013, 47, 1066–1080. [Google Scholar] [CrossRef] [PubMed]
- Lin, C.H.; Nicol, C.J.B.; Cheng, Y.C.; Yen, C.; Wang, Y.S.; Chiang, M.C. Neuroprotective effects of resveratrol against oxygen glucose deprivation induced mitochondrial dysfunction by activation of AMPK in SH-SY5Y cells with 3D gelatin scaffold. Brain Res. 2020, 1726, 146492. [Google Scholar] [CrossRef]
- Chen, Y.Y.; Zhang, L.; Shi, D.L.; Song, X.H.; Shen, Y.L.; Zheng, M.Z.; Wang, L.L. Resveratrol Attenuates Subacute Systemic Inflammation-Induced Spatial Memory Impairment via Inhibition of Astrocyte Activation and Enhancement of Synaptophysin Expression in the Hippocampus. Ann. Clin. Lab. Sci. 2017, 47, 17–24. [Google Scholar]
- Yang, A.J.T.; Frendo-Cumbo, S.; MacPherson, R.E.K. Resveratrol and metformin recover prefrontal cortex AMPK activation in diet-induced obese mice but reduce BDNF and synaptophysin protein content. J. Alzheimers Dis. 2019, 71, 945–956. [Google Scholar] [CrossRef]
- Yang, Y.M.; Chen, J.Z.; Wang, X.X.; Wang, S.J.; Hu, H.; Wang, H.Q. Resveratrol attenuates thromboxane A2 receptor agonist-induced platelet activation by reducing phospholipase C activity. Eur. J. Pharmacol. 2008, 583, 148–155. [Google Scholar] [CrossRef]
- Vasanthi, H.R.; ShriShriMal, N.; Das, D.K. Phytochemicals from plants to combat cardiovascular disease. Curr. Med. Chem. 2012, 19, 2242–2251. [Google Scholar] [CrossRef]
- Orallo, F.; Alvarez, E.; Camina, M.; Leiro, J.M.; Gomez, E.; Fernandez, P. The possible implication of trans-Resveratrol in the cardioprotective effects of long-term moderate wine consumption. Mol. Pharmacol. 2002, 61, 294–302. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Athar, M.; Back, J.H.; Tang, X.; Kim, K.H.; Kopelovich, L.; Bickers, D.R.; Kim, A.L. Resveratrol: A review of preclinical studies for human cancer prevention. Toxicol. Appl. Pharmacol. 2007, 224, 274–283. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kamaleddin, M.A. The paradoxical pro- and antiangiogenic actions of resveratrol: Therapeutic applications in cancer and diabetes. Ann. N. Y. Acad. Sci. 2016, 1386, 3–15. [Google Scholar] [CrossRef] [PubMed]
- Acharya, D.P.; Sanguansri, L.; Augustin, M.A. Binding of resveratrol with sodium caseinate in aqueous solutions. Food Chem. 2013, 141, 1050–1054. [Google Scholar] [CrossRef] [PubMed]
- Bourassa, P.; Bariyanga, J.; Tajmir-Riahi, H.A. Binding sites of resveratrol, genistein, and curcumin with milk alpha- and beta-caseins. J. Phys. Chem. B 2013, 117, 1287–1295. [Google Scholar] [CrossRef] [PubMed]
- Heelan, B.A.; Corrigan, O.I. In vitro analysis of the release of incorporated agents from sodium caseinate microspheres. J. Microencapsul. 1997, 14, 63–78. [Google Scholar] [CrossRef]
- Maier-Salamon, A.; Hagenauer, B.; Reznicek, G.; Szekeres, T.; Thalhammer, T.; Jager, W. Metabolism and disposition of resveratrol in the isolated perfused rat liver: Role of Mrp2 in the biliary excretion of glucuronides. J. Pharm. Sci. 2008, 97, 1615–1628. [Google Scholar] [CrossRef] [PubMed]
- Penalva, R.; Morales, J.; Gonzalez-Navarro, C.J.; Larraneta, E.; Quincoces, G.; Penuelas, I.; Irache, J.M. Increased oral bioavailability of resveratrol by its encapsulation in casein nanoparticles. Int. J. Mol. Sci. 2018, 19, 2816. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Elzoghby, A.O.; El-Fotoh, W.S.; Elgindy, N.A. Casein-based formulations as promising controlled release drug delivery systems. J. Control. Release 2011, 153, 206–216. [Google Scholar] [CrossRef]
- Kuhnle, G.; Spencer, J.P.; Chowrimootoo, G.; Schroeter, H.; Debnam, E.S.; Srai, S.K.; Rice-Evans, C.; Hahn, U. Resveratrol is absorbed in the small intestine as resveratrol glucuronide. Biochem. Biophys. Res. Commun. 2000, 272, 212–217. [Google Scholar] [CrossRef] [PubMed]
- Trevaskis, N.L.; Kaminskas, L.M.; Porter, C.J. From sewer to saviour—Targeting the lymphatic system to promote drug exposure and activity. Nat. Rev. Drug Discov. 2015, 14, 781–803. [Google Scholar] [CrossRef] [PubMed]
- Carrizzo, A.; Forte, M.; Damato, A.; Trimarco, V.; Salzano, F.; Bartolo, M.; Maciag, A.; Puca, A.A.; Vecchione, C. Antioxidant effects of resveratrol in cardiovascular, cerebral and metabolic diseases. Food Chem. Toxicol. 2013, 61, 215–226. [Google Scholar] [CrossRef]
- He, S.; Yan, X. From resveratrol to its derivatives: New sources of natural antioxidant. Curr. Med. Chem. 2013, 20, 1005–1017. [Google Scholar] [PubMed]
- Foti Cuzzola, V.; Ciurleo, R.; Giacoppo, S.; Marino, S.; Bramanti, P. Role of resveratrol and its analogues in the treatment of neurodegenerative diseases: Focus on recent discoveries. CNS Neurol. Disord. Drug Targets 2011, 10, 849–862. [Google Scholar] [CrossRef]
- Pallas, M.; Porquet, D.; Vicente, A.; Sanfeliu, C. Resveratrol: New avenues for a natural compound in neuroprotection. Curr. Pharm. Des. 2013, 19, 6726–6731. [Google Scholar] [CrossRef] [Green Version]
- Kreuter, J.; Shamenkov, D.; Petrov, V.; Ramge, P.; Cychutek, K.; Koch-Brandt, C.; Alyautdin, R. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J. Drug Target 2002, 10, 317–325. [Google Scholar] [CrossRef]
- Petri, B.; Bootz, A.; Khalansky, A.; Hekmatara, T.; Muller, R.; Uhl, R.; Kreuter, J.; Gelperina, S. Chemotherapy of brain tumour using doxorubicin bound to surfactant-coated poly(butyl cyanoacrylate) nanoparticles: Revisiting the role of surfactants. J. Control. Release 2007, 117, 51–58. [Google Scholar] [CrossRef]
- Prediger, R.D.; Aguiar, A.S., Jr.; Matheus, F.C.; Walz, R.; Antoury, L.; Raisman-Vozari, R.; Doty, R.L. Intranasal administration of neurotoxicants in animals: Support for the olfactory vector hypothesis of Parkinson’s disease. Neurotox. Res. 2012, 21, 90–116. [Google Scholar] [CrossRef]
- Crotty, G.F.; Ascherio, A.; Schwarzschild, M.A. Targeting urate to reduce oxidative stress in Parkinson disease. Exp. Neurol. 2017, 298, 210–224. [Google Scholar] [CrossRef]
- Saddick, S.; Afifi, M.; Abu Zinada, O.A. Effect of Zinc nanoparticles on oxidative stress-related genes and antioxidant enzymes activity in the brain of Oreochromis niloticus and Tilapia zillii. Saudi J. Biol. Sci. 2017, 24, 1672–1678. [Google Scholar] [CrossRef]
- Henchcliffe, C.; Beal, M.F. Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat. Clin. Pract. Neurol. 2008, 4, 600–609. [Google Scholar] [CrossRef] [PubMed]
- Kubo, Y. Carrier-mediated Transport of Cationic Drugs across the Blood-Tissue Barrier. Yakugaku Zasshi 2015, 135, 1135–1140. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wohlfart, S.; Gelperina, S.; Kreuter, J. Transport of drugs across the blood-brain barrier by nanoparticles. J. Control. Release 2012, 161, 264–273. [Google Scholar] [CrossRef] [PubMed]
- Peppas, N.A. 1. Commentary on an exponential model for the analysis of drug delivery: Original research article: A simple equation for description of solute release: I II. Fickian and non-Fickian release from non-swellable devices in the form of slabs, spheres, cylinders or discs, 1987. J. Control. Release 2014, 190, 31–32. [Google Scholar]
- Gelperina, S.; Maksimenko, O.; Khalansky, A.; Vanchugova, L.; Shipulo, E.; Abbasova, K.; Berdiev, R.; Wohlfart, S.; Chepurnova, N.; Kreuter, J. Drug delivery to the brain using surfactant-coated poly(lactide-co-glycolide) nanoparticles: Influence of the formulation parameters. Eur. J. Pharm. Biopharm. 2010, 74, 157–163. [Google Scholar] [CrossRef]
- Kreuter, J. Nanoparticulate systems for brain delivery of drugs. Adv. Drug Deliv. Rev. 2001, 47, 65–81. [Google Scholar] [CrossRef]
- Goppert, T.M.; Muller, R.H. Polysorbate-stabilized solid lipid nanoparticles as colloidal carriers for intravenous targeting of drugs to the brain: Comparison of plasma protein adsorption patterns. J. Drug Target 2005, 13, 179–187. [Google Scholar] [CrossRef]
- Karthikeyan, K.; Lakra, R.; Rajaram, R.; Korrapati, P.S. Development and characterization of zein-based microcarrier system for sustained delivery of aceclofenac sodium. AAPS Pharm. Sci. Tech. 2012, 13, 143–149. [Google Scholar] [CrossRef] [Green Version]
- Paliwal, R.; Palakurthi, S. Zein in controlled drug delivery and tissue engineering. J. Control. Release 2014, 189, 108–122. [Google Scholar] [CrossRef] [PubMed]
- Shi, K.; Kokini, J.L.; Huang, Q. Engineering zein films with controlled surface morphology and hydrophilicity. J. Agric. Food Chem. 2009, 57, 2186–2192. [Google Scholar] [CrossRef] [PubMed]
- Penalva, R.; Esparza, I.; Larraneta, E.; Gonzalez-Navarro, C.J.; Gamazo, C.; Irache, J.M. Zein-based nanoparticles improve the oral bioavailability of resveratrol and its anti-inflammatory effects in a mouse model of endotoxic shock. J. Agric. Food Chem. 2015, 63, 5603–5611. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Teskac, K.; Kristl, J. The evidence for solid lipid nanoparticles mediated cell uptake of resveratrol. Int. J. Pharm. 2010, 390, 61–69. [Google Scholar] [CrossRef] [PubMed]
- Singh, G.; Pai, R.S. Optimized PLGA nanoparticle platform for orally dosed trans-resveratrol with enhanced bioavailability potential. Expert Opin. Drug Deliv. 2014, 11, 647–659. [Google Scholar] [CrossRef]
- Yang, Y.; Li, S.; Yang, Q.; Shi, Y.; Zheng, M.; Liu, Y.; Chen, F.; Song, G.; Xu, H.; Wan, T.; et al. Resveratrol reduces the proinflammatory effects and lipopolysaccharide- induced expression of HMGB1 and TLR4 in RAW264.7 cells. Cell. Physiol. Biochem. 2014, 33, 1283–1292. [Google Scholar] [CrossRef]
- Nemzek, J.A.; Hugunin, K.M.; Opp, M.R. Modeling sepsis in the laboratory: Merging sound science with animal well-being. Comp. Med. 2008, 58, 120–128. [Google Scholar]
- Farghali, H.; Cerny, D.; Kamenikova, L.; Martinek, J.; Horinek, A.; Kmonickova, E.; Zidek, Z. Resveratrol attenuates lipopolysaccharide-induced hepatitis in D-galactosamine sensitized rats: Role of nitric oxide synthase 2 and heme oxygenase-1. Nitric Oxide 2009, 21, 216–225. [Google Scholar] [CrossRef]
- Murata, Y.; Miyashita, M.; Kofuji, K.; Miyamoto, E.; Kawashima, S. Drug release properties of a gel bead prepared with pectin and hydrolysate. J. Control. Release 2004, 95, 61–66. [Google Scholar] [CrossRef]
- Sriamornsak, P.; Nunthanid, J. Calcium pectinate gel beads for controlled release drug delivery: II. Effect of formulation and processing variables on drug release. J. Microencapsul. 1999, 16, 303–313. [Google Scholar] [CrossRef]
- El-Gibaly, I. Oral delayed-release system based on Zn-pectinate gel (ZPG) microparticles as an alternative carrier to calcium pectinate beads for colonic drug delivery. Int. J. Pharm. 2002, 232, 199–211. [Google Scholar] [CrossRef]
- Dupuis, G.; Chambin, O.; Genelot, C.; Champion, D.; Pourcelot, Y. Colonic drug delivery: Influence of cross-linking agent on pectin beads properties and role of the shell capsule type. Drug Dev. Ind. Pharm. 2006, 32, 847–855. [Google Scholar] [CrossRef] [PubMed]
- Chambin, O.; Dupuis, G.; Champion, D.; Voilley, A.; Pourcelot, Y. Colon-specific drug delivery: Influence of solution reticulation properties upon pectin beads performance. Int. J. Pharm. 2006, 321, 86–93. [Google Scholar] [CrossRef]
- Maestrelli, F.; Cirri, M.; Corti, G.; Mennini, N.; Mura, P. Development of enteric-coated calcium pectinate microspheres intended for colonic drug delivery. Eur. J. Pharm. Biopharm. 2008, 69, 508–518. [Google Scholar] [CrossRef] [PubMed]
- Liu, L.; Fishman, M.L.; Kost, J.; Hicks, K.B. Pectin-based systems for colon-specific drug delivery via oral route. Biomaterials 2003, 24, 3333–3343. [Google Scholar] [CrossRef]
- Basit, A.W. Advances in colonic drug delivery. Drugs 2005, 65, 1991–2007. [Google Scholar] [CrossRef] [PubMed]
- Friend, D.R. New oral delivery systems for treatment of inflammatory bowel disease. Adv. Drug Deliv. Rev. 2005, 57, 247–265. [Google Scholar] [CrossRef] [PubMed]
- Das, S.; Ng, K.Y. Colon-specific delivery of resveratrol: Optimization of multi-particulate calcium-pectinate carrier. Int. J. Pharm. 2010, 385, 20–28. [Google Scholar] [CrossRef]
- Das, S.; Ng, K.Y. Resveratrol-loaded calcium-pectinate beads: Effects of formulation parameters on drug release and bead characteristics. J. Pharm. Sci. 2010, 99, 840–860. [Google Scholar] [CrossRef]
- Das, S.; Ng, K.Y.; Ho, P.C. Formulation and optimization of zinc-pectinate beads for the controlled delivery of resveratrol. AAPS Pharm. Sci. Tech. 2010, 11, 729–742. [Google Scholar] [CrossRef]
- Sriamornsak, P. Effect of calcium concentration, hardening agent and drying condition on release characteristics of oral proteins from calcium pectinate gel beads. Eur. J. Pharm. Sci. 1999, 8, 221–227. [Google Scholar] [CrossRef]
- Kaldas, M.I.; Walle, U.K.; Walle, T. Resveratrol transport and metabolism by human intestinal Caco-2 cells. J. Pharm. Pharmacol. 2003, 55, 307–312. [Google Scholar] [CrossRef] [PubMed]
- Maier-Salamon, A.; Hagenauer, B.; Wirth, M.; Gabor, F.; Szekeres, T.; Jager, W. Increased transport of resveratrol across monolayers of the human intestinal Caco-2 cells is mediated by inhibition and saturation of metabolites. Pharm. Res. 2006, 23, 2107–2115. [Google Scholar] [CrossRef] [PubMed]
- Walle, T.; Hsieh, F.; DeLegge, M.H.; Oatis, J.E., Jr.; Walle, U.K. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab. Dispos. 2004, 32, 1377–1382. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mehnert, W.; Mader, K. Solid lipid nanoparticles: Production, characterization and applications. Adv. Drug Deliv. Rev. 2001, 47, 165–196. [Google Scholar] [CrossRef]
- Muller, R.H.; Mader, K.; Gohla, S. Solid lipid nanoparticles (SLN) for controlled drug delivery—A review of the state of the art. Eur. J. Pharm. Biopharm. 2000, 50, 161–177. [Google Scholar] [CrossRef]
- Kuchler, S.; Wolf, N.B.; Heilmann, S.; Weindl, G.; Helfmann, J.; Yahya, M.M.; Stein, C.; Schafer-Korting, M. 3D-wound healing model: Influence of morphine and solid lipid nanoparticles. J. Biotechnol. 2010, 148, 24–30. [Google Scholar] [CrossRef]
- Dingler, A.; Blum, R.P.; Niehus, H.; Muller, R.H.; Gohla, S. Solid lipid nanoparticles (SLN/Lipopearls)—A pharmaceutical and cosmetic carrier for the application of vitamin E in dermal products. J. Microencapsul. 1999, 16, 751–767. [Google Scholar] [CrossRef]
- Puglia, C.; Filosa, R.; Peduto, A.; de Caprariis, P.; Rizza, L.; Bonina, F.; Blasi, P. Evaluation of alternative strategies to optimize ketorolac transdermal delivery. AAPS Pharm. Sci. Tech. 2006, 7, 64. [Google Scholar] [CrossRef] [Green Version]
- Souto, E.B.; Wissing, S.A.; Barbosa, C.M.; Muller, R.H. Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery. Int. J. Pharm. 2004, 278, 71–77. [Google Scholar] [CrossRef] [PubMed]
- Teeranachaideekul, V.; Muller, R.H.; Junyaprasert, V.B. Encapsulation of ascorbyl palmitate in nanostructured lipid carriers (NLC)--effects of formulation parameters on physicochemical stability. Int. J. Pharm. 2007, 340, 198–206. [Google Scholar] [CrossRef] [PubMed]
- Pardeike, J.; Hommoss, A.; Muller, R.H. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int. J. Pharm. 2009, 366, 170–184. [Google Scholar] [CrossRef] [PubMed]
- Wu, F.M.; Wang, N.; Pang, S.F.; Zhang, Y.H. Hygroscopic behavior and fractional crystallization of mixed (NH4)2SO4/glutaric acid aerosols by vacuum FTIR. Spectrochim. Acta A Mol. Biomol. Spectrosc. 2019, 208, 255–261. [Google Scholar] [CrossRef] [PubMed]
- Jenning, V.; Thunemann, A.F.; Gohla, S.H. Characterisation of a novel solid lipid nanoparticle carrier system based on binary mixtures of liquid and solid lipids. Int. J. Pharm. 2000, 199, 167–177. [Google Scholar] [CrossRef]
- Uner, M.; Yener, G. Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives. Int. J. Nanomed. 2007, 2, 289–300. [Google Scholar]
- Gokce, E.H.; Korkmaz, E.; Dellera, E.; Sandri, G.; Bonferoni, M.C.; Ozer, O. Resveratrol-loaded solid lipid nanoparticles versus nanostructured lipid carriers: Evaluation of antioxidant potential for dermal applications. Int. J. Nanomed. 2012, 7, 1841–1850. [Google Scholar] [CrossRef] [Green Version]
- Volpedo, G.; Costa, L.; Ryan, N.; Halsey, G.; Satoskar, A.; Oghumu, S. Nanoparticulate drug delivery systems for the treatment of neglected tropical protozoan diseases. J. Venom. Anim. Toxins Incl. Trop Dis. 2019, 25, e144118. [Google Scholar] [CrossRef]
- Trombino, S.; Cassano, R.; Muzzalupo, R.; Pingitore, A.; Cione, E.; Picci, N. Stearyl ferulate-based solid lipid nanoparticles for the encapsulation and stabilization of beta-carotene and alpha-tocopherol. Colloids Surf. B Biointerfaces 2009, 72, 181–187. [Google Scholar] [CrossRef]
- Ruktanonchai, U.; Bejrapha, P.; Sakulkhu, U.; Opanasopit, P.; Bunyapraphatsara, N.; Junyaprasert, V.; Puttipipatkhachorn, S. Physicochemical characteristics, cytotoxicity, and antioxidant activity of three lipid nanoparticulate formulations of alpha-lipoic acid. AAPS Pharm. Sci. Tech. 2009, 10, 227–234. [Google Scholar] [CrossRef] [Green Version]
- Cullis, P.R.; Chonn, A.; Semple, S.C. Interactions of liposomes and lipid-based carrier systems with blood proteins: Relation to clearance behaviour in vivo. Adv. Drug Deliv. Rev. 1998, 32, 3–17. [Google Scholar] [CrossRef]
- Hayes, M.E.; Drummond, D.C.; Hong, K.; Zheng, W.W.; Khorosheva, V.A.; Cohen, J.A.; Th, C.O.N.; Park, J.W.; Marks, J.D.; Benz, C.C.; et al. Increased target specificity of anti-HER2 genospheres by modification of surface charge and degree of PEGylation. Mol. Pharm. 2006, 3, 726–736. [Google Scholar] [CrossRef]
- Corti, G.; Maestrelli, F.; Cirri, M.; Zerrouk, N.; Mura, P. Development and evaluation of an in vitro method for prediction of human drug absorption II. Demonstration of the method suitability. Eur. J. Pharm. Sci. 2006, 27, 354–362. [Google Scholar] [CrossRef] [PubMed]
- Artursson, P.; Palm, K.; Luthman, K. Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv. Drug Deliv. Rev. 2001, 46, 27–43. [Google Scholar] [CrossRef]
- Schwebel, H.J.; van Hoogevest, P.; Leigh, M.L.; Kuentz, M. The apparent solubilizing capacity of simulated intestinal fluids for poorly water-soluble drugs. Pharm. Dev. Technol. 2011, 16, 278–286. [Google Scholar] [CrossRef] [PubMed]
- Frank, K.J.; Westedt, U.; Rosenblatt, K.M.; Holig, P.; Rosenberg, J.; Magerlein, M.; Brandl, M.; Fricker, G. Impact of FaSSIF on the solubility and dissolution-/permeation rate of a poorly water-soluble compound. Eur. J. Pharm. Sci. 2012, 47, 16–20. [Google Scholar] [CrossRef]
- Khan, M.K.; Hunter, G.K.; Vogelbaum, M.; Suh, J.H.; Chao, S.T. Evidence-based adjuvant therapy for gliomas: current concepts and newer developments. Indian J. Cancer 2009, 46, 96–107. [Google Scholar] [CrossRef] [Green Version]
- Jiang, H.; Shang, X.; Wu, H.; Huang, G.; Wang, Y.; Al-Holou, S.; Gautam, S.C.; Chopp, M. Combination treatment with resveratrol and sulforaphane induces apoptosis in human U251 glioma cells. Neurochem. Res. 2010, 35, 152–161. [Google Scholar] [CrossRef] [Green Version]
- Castino, R.; Pucer, A.; Veneroni, R.; Morani, F.; Peracchio, C.; Lah, T.T.; Isidoro, C. Resveratrol reduces the invasive growth and promotes the acquisition of a long-lasting differentiated phenotype in human glioblastoma cells. J. Agric. Food Chem. 2011, 59, 4264–4272. [Google Scholar] [CrossRef]
- Yang, J.; Nagasawa, D.T.; Spasic, M.; Amolis, M.; Choy, W.; Garcia, H.M.; Prins, R.M.; Liau, L.M.; Yang, I. Endogenous vaults and bioengineered vault nanoparticles for treatment of glioblastomas: Implications for future targeted therapies. Neurosurg. Clin. N. Am. 2012, 23, 451–458. [Google Scholar] [CrossRef]
- Zhang, P.; Hu, L.; Yin, Q.; Feng, L.; Li, Y. Transferrin-modified c[RGDfK]-paclitaxel loaded hybrid micelle for sequential blood-brain barrier penetration and glioma targeting therapy. Mol. Pharm. 2012, 9, 1590–1598. [Google Scholar] [CrossRef]
- Gao, X.; Tao, W.; Lu, W.; Zhang, Q.; Zhang, Y.; Jiang, X.; Fu, S. Lectin-conjugated PEG-PLA nanoparticles: Preparation and brain delivery after intranasal administration. Biomaterials 2006, 27, 3482–3490. [Google Scholar] [CrossRef]
- Panyam, J.; Labhasetwar, V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv. Drug Deliv. Rev. 2003, 55, 329–347. [Google Scholar] [CrossRef]
- Chandana, S.R.; Movva, S.; Arora, M.; Singh, T. Primary brain tumors in adults. Am. Fam. Physician 2008, 77, 1423–1430. [Google Scholar] [PubMed]
- Huang, R.Q.; Qu, Y.H.; Ke, W.L.; Zhu, J.H.; Pei, Y.Y.; Jiang, C. Efficient gene delivery targeted to the brain using a transferrin-conjugated polyethyleneglycol-modified polyamidoamine dendrimer. FASEB J. 2007, 21, 1117–1125. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Daniels, T.R.; Delgado, T.; Helguera, G.; Penichet, M.L. The transferrin receptor part II: Targeted delivery of therapeutic agents into cancer cells. Clin. Immunol. 2006, 121, 159–176. [Google Scholar] [CrossRef]
- Calzolari, A.; Larocca, L.M.; Deaglio, S.; Finisguerra, V.; Boe, A.; Raggi, C.; Ricci-Vitani, L.; Pierconti, F.; Malavasi, F.; De Maria, R.; et al. Transferrin receptor 2 is frequently and highly expressed in glioblastomas. Transl. Oncol. 2010, 3, 123–134. [Google Scholar] [CrossRef] [Green Version]
- Siddiqui, I.A.; Adhami, V.M.; Bharali, D.J.; Hafeez, B.B.; Asim, M.; Khwaja, S.I.; Ahmad, N.; Cui, H.; Mousa, S.A.; Mukhtar, H. Introducing nanochemoprevention as a novel approach for cancer control: Proof of principle with green tea polyphenol epigallocatechin-3-gallate. Cancer Res. 2009, 69, 1712–1716. [Google Scholar] [CrossRef] [Green Version]
- Zhu, S.; Hong, M.; Tang, G.; Qian, L.; Lin, J.; Jiang, Y.; Pei, Y. Partly PEGylated polyamidoamine dendrimer for tumor-selective targeting of doxorubicin: The effects of PEGylation degree and drug conjugation style. Biomaterials 2010, 31, 1360–1371. [Google Scholar] [CrossRef]
- Barnes, S.; Quinlan, R.A. Small molecules, both dietary and endogenous, influence the onset of lens cataracts. Exp. Eye Res. 2017, 156, 87–94. [Google Scholar] [CrossRef] [Green Version]
- Vora, D.; Heruye, S.; Kumari, D.; Opere, C.; Chauhan, H. Preparation, Characterization and antioxidant evaluation of poorly soluble polyphenol-loaded nanoparticles for cataract treatment. AAPS Pharm. Sci. Tech. 2019, 20, 163. [Google Scholar] [CrossRef]
- Liu, Y.; Wu, Y.M.; Yu, Y.; Cao, C.S.; Zhang, J.H.; Li, K.; Zhang, P.Y. Curcumin and resveratrol in combination modulate drug-metabolizing enzymes as well as antioxidant indices during lung carcinogenesis in mice. Hum. Exp. Toxicol. 2015, 34, 620–627. [Google Scholar] [CrossRef]
- Musazzi, U.M.; Youm, I.; Murowchick, J.B.; Ezoulin, M.J.; Youan, B.B. Resveratrol-loaded nanocarriers: Formulation, optimization, characterization and in vitro toxicity on cochlear cells. Colloids Surf. B Biointerfaces 2014, 118, 234–242. [Google Scholar] [CrossRef] [PubMed]
- Rybak, L.P.; Mukherjea, D.; Ramkumar, V. Mechanisms of cisplatin-induced ototoxicity and prevention. Semin. Hear 2019, 40, 197–204. [Google Scholar] [CrossRef] [PubMed]
- Bragado, P.; Armesilla, A.; Silva, A.; Porras, A. Apoptosis by cisplatin requires p53 mediated p38alpha MAPK activation through ROS generation. Apoptosis 2007, 12, 1733–1742. [Google Scholar] [CrossRef] [PubMed]
- Alam, S.A.; Ikeda, K.; Oshima, T.; Suzuki, M.; Kawase, T.; Kikuchi, T.; Takasaka, T. Cisplatin-induced apoptotic cell death in Mongolian gerbil cochlea. Hear Res. 2000, 141, 28–38. [Google Scholar] [CrossRef]
- Lu, X.; Ji, C.; Xu, H.; Li, X.; Ding, H.; Ye, M.; Zhu, Z.; Ding, D.; Jiang, X.; Ding, X.; et al. Resveratrol-loaded polymeric micelles protect cells from Abeta-induced oxidative stress. Int. J. Pharm. 2009, 375, 89–96. [Google Scholar] [CrossRef] [PubMed]
- Wegiel, L.A.; Mauer, L.J.; Edgar, K.J.; Taylor, L.S. Crystallization of amorphous solid dispersions of resveratrol during preparation and storage-Impact of different polymers. J. Pharm. Sci. 2013, 102, 171–184. [Google Scholar] [CrossRef] [PubMed]
- Abdelwahed, W.; Degobert, G.; Stainmesse, S.; Fessi, H. Freeze-drying of nanoparticles: Formulation, process and storage considerations. Adv. Drug Deliv. Rev. 2006, 58, 1688–1713. [Google Scholar] [CrossRef]
- Rozmanov, D.; Kusalik, P.G. Anisotropy in the crystal growth of hexagonal ice, I(h). J. Chem. Phys. 2012, 137, 094702. [Google Scholar] [CrossRef]
- Zhang, Y.; Zhang, W.; Lobler, M.; Schmitz, K.P.; Saulnier, P.; Perrier, T.; Pyykko, I.; Zou, J. Inner ear biocompatibility of lipid nanocapsules after round window membrane application. Int. J. Pharm. 2011, 404, 211–219. [Google Scholar] [CrossRef] [PubMed]
- Kalinec, G.M.; Webster, P.; Lim, D.J.; Kalinec, F. A cochlear cell line as an in vitro system for drug ototoxicity screening. Audiol. Neurootol. 2003, 8, 177–189. [Google Scholar] [CrossRef]
- Rivolta, M.N.; Holley, M.C. Cell lines in inner ear research. J. Neurobiol. 2002, 53, 306–318. [Google Scholar] [CrossRef]
- Borgnakke, W.S.; Ylostalo, P.V.; Taylor, G.W.; Genco, R.J. Effect of periodontal disease on diabetes: systematic review of epidemiologic observational evidence. J. Periodontol. 2013, 84, S135–S152. [Google Scholar] [CrossRef] [Green Version]
- Aspriello, S.D.; Zizzi, A.; Tirabassi, G.; Buldreghini, E.; Biscotti, T.; Faloia, E.; Stramazzotti, D.; Boscaro, M.; Piemontese, M. Diabetes mellitus-associated periodontitis: differences between type 1 and type 2 diabetes mellitus. J. Periodontal. Res. 2011, 46, 164–169. [Google Scholar] [CrossRef]
- Kamimura, D.; Ishihara, K.; Hirano, T. IL-6 signal transduction and its physiological roles: The signal orchestration model. Rev. Physiol. Biochem. Pharmacol. 2003, 149, 1–38. [Google Scholar] [CrossRef]
- Kristiansen, O.P.; Mandrup-Poulsen, T. Interleukin-6 and diabetes: The good, the bad, or the indifferent? Diabetes 2005, 54, S114–S124. [Google Scholar] [CrossRef] [Green Version]
- Hughes, F.J.; Turner, W.; Belibasakis, G.; Martuscelli, G. Effects of growth factors and cytokines on osteoblast differentiation. Periodontol 2000 2006, 41, 48–72. [Google Scholar] [CrossRef]
- Lozano-Perez, A.A.; Rivero, H.C.; Perez Hernandez, M.D.C.; Pagan, A.; Montalban, M.G.; Villora, G.; Cenis, J.L. Silk fibroin nanoparticles: Efficient vehicles for the natural antioxidant quercetin. Int. J. Pharm. 2017, 518, 11–19. [Google Scholar] [CrossRef]
- Montalban, M.G.; Coburn, J.M.; Lozano-Perez, A.A.; Cenis, J.L.; Villora, G.; Kaplan, D.L. production of curcumin-loaded silk fibroin nanoparticles for cancer therapy. Nanomaterials (Basel) 2018, 8, 126. [Google Scholar] [CrossRef] [Green Version]
- Lozano-Perez, A.A.; Rodriguez-Nogales, A.; Ortiz-Cullera, V.; Algieri, F.; Garrido-Mesa, J.; Zorrilla, P.; Rodriguez-Cabezas, M.E.; Garrido-Mesa, N.; Utrilla, M.P.; De Matteis, L.; et al. Silk fibroin nanoparticles constitute a vector for controlled release of resveratrol in an experimental model of inflammatory bowel disease in rats. Int. J. Nanomed. 2014, 9, 4507–4520. [Google Scholar] [CrossRef] [Green Version]
- Ebersole, J.L.; Schuster, J.L.; Stevens, J.; Dawson, D., 3rd; Kryscio, R.J.; Lin, Y.; Thomas, M.V.; Miller, C.S. Patterns of salivary analytes provide diagnostic capacity for distinguishing chronic adult periodontitis from health. J. Clin. Immunol. 2013, 33, 271–279. [Google Scholar] [CrossRef]
- Correa, M.G.; Pires, P.R.; Ribeiro, F.V.; Pimentel, S.Z.; Casarin, R.C.; Cirano, F.R.; Tenenbaum, H.T.; Casati, M.Z. Systemic treatment with resveratrol and/or curcumin reduces the progression of experimental periodontitis in rats. J. Periodontal. Res. 2017, 52, 201–209. [Google Scholar] [CrossRef]
- Lorencini, M.; Silva, J.A.; Almeida, C.A.; Bruni-Cardoso, A.; Carvalho, H.F.; Stach-Machado, D.R. A new paradigm in the periodontal disease progression: Gingival connective tissue remodeling with simultaneous collagen degradation and fibers thickening. Tissue Cell 2009, 41, 43–50. [Google Scholar] [CrossRef]
- Seguier, S.; Gogly, B.; Bodineau, A.; Godeau, G.; Brousse, N. Is collagen breakdown during periodontitis linked to inflammatory cells and expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human gingival tissue? J. Periodontol. 2001, 72, 1398–1406. [Google Scholar] [CrossRef]
- Kasprzak, A.; Surdacka, A.; Tomczak, M.; Przybyszewska, W.; Seraszek-Jaros, A.; Malkowska-Lanzafame, A.; Siodla, E.; Kaczmarek, E. Expression of angiogenesis-stimulating factors (VEGF, CD31, CD105) and angiogenetic index in gingivae of patients with chronic periodontitis. Folia Histochem. Cytobiol. 2012, 50, 554–564. [Google Scholar] [CrossRef]
- Jang, J.H.; Surh, Y.J. Protective effect of resveratrol on beta-amyloid-induced oxidative PC12 cell death. Free Radic. Biol. Med. 2003, 34, 1100–1110. [Google Scholar] [CrossRef]
- Russo, A.; Palumbo, M.; Aliano, C.; Lempereur, L.; Scoto, G.; Renis, M. Red wine micronutrients as protective agents in Alzheimer-like induced insult. Life Sci. 2003, 72, 2369–2379. [Google Scholar] [CrossRef]
- Sharma, M.; Gupta, Y.K. Chronic treatment with trans resveratrol prevents intracerebroventricular streptozotocin induced cognitive impairment and oxidative stress in rats. Life Sci. 2002, 71, 2489–2498. [Google Scholar] [CrossRef]
- Mancuso, C.; Bates, T.E.; Butterfield, D.A.; Calafato, S.; Cornelius, C.; De Lorenzo, A.; Dinkova Kostova, A.T.; Calabrese, V. Natural antioxidants in Alzheimer’s disease. Expert. Opin. Investig. Drugs 2007, 16, 1921–1931. [Google Scholar] [CrossRef]
- Anekonda, T.S. Resveratrol--a boon for treating Alzheimer’s disease? Brain Res. Rev. 2006, 52, 316–326. [Google Scholar] [CrossRef]
- Zhang, L.; Hu, Y.; Jiang, X.; Yang, C.; Lu, W.; Yang, Y.H. Camptothecin derivative-loaded poly(caprolactone-co-lactide)-b-PEG-b-poly(caprolactone-co-lactide) nanoparticles and their biodistribution in mice. J. Control. Release 2004, 96, 135–148. [Google Scholar] [CrossRef]
- Galati, G.; Sabzevari, O.; Wilson, J.X.; O’Brien, P.J. Prooxidant activity and cellular effects of the phenoxyl radicals of dietary flavonoids and other polyphenolics. Toxicology 2002, 177, 91–104. [Google Scholar] [CrossRef]
- Davda, J.; Labhasetwar, V. Characterization of nanoparticle uptake by endothelial cells. Int. J. Pharm. 2002, 233, 51–59. [Google Scholar] [CrossRef]
- Devalapally, H.; Shenoy, D.; Little, S.; Langer, R.; Amiji, M. Poly(ethylene oxide)-modified poly(beta-amino ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs: Part 3. Therapeutic efficacy and safety studies in ovarian cancer xenograft model. Cancer Chemother. Pharmacol. 2007, 59, 477–484. [Google Scholar] [CrossRef]
- Caddeo, C.; Teskac, K.; Sinico, C.; Kristl, J. Effect of resveratrol incorporated in liposomes on proliferation and UV-B protection of cells. Int. J. Pharm. 2008, 363, 183–191. [Google Scholar] [CrossRef]
- Jang, M.H.; Piao, X.L.; Kim, H.Y.; Cho, E.J.; Baek, S.H.; Kwon, S.W.; Park, J.H. Resveratrol oligomers from Vitis amurensis attenuate beta-amyloid-induced oxidative stress in PC12 cells. Biol. Pharm. Bull. 2007, 30, 1130–1134. [Google Scholar] [CrossRef] [Green Version]
- Yamagishi, S.; Matsui, T. Advanced glycation end products (AGEs), oxidative stress and diabetic retinopathy. Curr. Pharm. Biotechnol. 2011, 12, 362–368. [Google Scholar] [CrossRef]
- Barber, A.J.; Gardner, T.W.; Abcouwer, S.F. The significance of vascular and neural apoptosis to the pathology of diabetic retinopathy. Investig. Ophthalmol. Vis. Sci. 2011, 52, 1156–1163. [Google Scholar] [CrossRef]
- Singh, C.K.; Kumar, A.; Hitchcock, D.B.; Fan, D.; Goodwin, R.; LaVoie, H.A.; Nagarkatti, P.; DiPette, D.J.; Singh, U.S. Resveratrol prevents embryonic oxidative stress and apoptosis associated with diabetic embryopathy and improves glucose and lipid profile of diabetic dam. Mol. Nutr. Food Res. 2011, 55, 1186–1196. [Google Scholar] [CrossRef] [Green Version]
- Dong, Y.; Wan, G.; Yan, P.; Qian, C.; Li, F.; Peng, G. Fabrication of resveratrol coated gold nanoparticles and investigation of their effect on diabetic retinopathy in streptozotocin induced diabetic rats. J. Photochem. Photobiol. B. 2019, 195, 51–57. [Google Scholar] [CrossRef]
- Sinha, D.; Sarkar, N.; Biswas, J.; Bishayee, A. Resveratrol for breast cancer prevention and therapy: Preclinical evidence and molecular mechanisms. Semin. Cancer Biol. 2016, 40-41, 209–232. [Google Scholar] [CrossRef]
- Fan, C.; Kong, F.; Shetti, D.; Zhang, B.; Yang, Y.; Wei, K. Resveratrol loaded oxidized mesoporous carbon nanoparticles: A promising tool to treat triple negative breast cancer. Biochem. Biophys. Res. Commun. 2019, 519, 378–384. [Google Scholar] [CrossRef]
- Zhang, Y.; Zhi, Z.; Li, X.; Gao, J.; Song, Y. Carboxylated mesoporous carbon microparticles as new approach to improve the oral bioavailability of poorly water-soluble carvedilol. Int. J. Pharm. 2013, 454, 403–411. [Google Scholar] [CrossRef]
- Al-Hassan, J.M.; Fang Liu, Y.; Khan, M.A.; Yang, P.; Guan, R.; Wen, X.Y.; Afzal, M.; Oommen, S.; Paul, B.M.; Nair, D.; et al. Furanoic lipid F-6, a novel anti-cancer compound that kills cancer cells by suppressing proliferation and inducing apoptosis. Cancers (Basel) 2019, 11, 960. [Google Scholar] [CrossRef] [Green Version]
- Hu, C.M.; Zhang, L. Nanoparticle-based combination therapy toward overcoming drug resistance in cancer. Biochem. Pharmacol. 2012, 83, 1104–1111. [Google Scholar] [CrossRef]
- Rompicharla, S.V.K.; Bhatt, H.; Shah, A.; Komanduri, N.; Vijayasarathy, D.; Ghosh, B.; Biswas, S. Formulation optimization, characterization, and evaluation of in vitro cytotoxic potential of curcumin loaded solid lipid nanoparticles for improved anticancer activity. Chem. Phys. Lipids 2017, 208, 10–18. [Google Scholar] [CrossRef]
- Senthil Kumar, C.; Thangam, R.; Mary, S.A.; Kannan, P.R.; Arun, G.; Madhan, B. Targeted delivery and apoptosis induction of trans-resveratrol-ferulic acid loaded chitosan coated folic acid conjugate solid lipid nanoparticles in colon cancer cells. Carbohydr. Polym. 2020, 231, 115682. [Google Scholar] [CrossRef]
- Kumar, C.S.; Raja, M.D.; Sundar, D.S.; Gover Antoniraj, M.; Ruckmani, K. Hyaluronic acid co-functionalized gold nanoparticle complex for the targeted delivery of metformin in the treatment of liver cancer (HepG2 cells). Carbohydr. Polym. 2015, 128, 63–74. [Google Scholar] [CrossRef]
- San Hipolito-Luengo, A.; Alcaide, A.; Ramos-Gonzalez, M.; Cercas, E.; Vallejo, S.; Romero, A.; Talero, E.; Sanchez-Ferrer, C.F.; Motilva, V.; Peiro, C. Dual Effects of Resveratrol on Cell Death and Proliferation of Colon Cancer Cells. Nutr. Cancer 2017, 69, 1019–1027. [Google Scholar] [CrossRef]
- Doss, H.M.; Samarpita, S.; Ganesan, R.; Rasool, M. Ferulic acid, a dietary polyphenol suppresses osteoclast differentiation and bone erosion via the inhibition of RANKL dependent NF-kappaB signalling pathway. Life Sci. 2018, 207, 284–295. [Google Scholar] [CrossRef]
- Thangam, R.; Senthilkumar, D.; Suresh, V.; Sathuvan, M.; Sivasubramanian, S.; Pazhanichamy, K.; Gorlagunta, P.K.; Kannan, S.; Gunasekaran, P.; Rengasamy, R.; et al. Induction of ROS-dependent mitochondria-mediated intrinsic apoptosis in MDA-MB-231 cells by glycoprotein from Codium decorticatum. J. Agric. Food Chem. 2014, 62, 3410–3421. [Google Scholar] [CrossRef]
- Liu, Y.; Liu, Y.; Yan, X.; Xu, Y.; Luo, F.; Ye, J.; Yan, H.; Yang, X.; Huang, X.; Zhang, J.; et al. HIFs enhance the migratory and neoplastic capacities of hepatocellular carcinoma cells by promoting EMT. Tumour. Biol. 2014, 35, 8103–8114. [Google Scholar] [CrossRef]
- Rankin, E.B.; Giaccia, A.J. Hypoxic control of metastasis. Science 2016, 352, 175–180. [Google Scholar] [CrossRef] [Green Version]
- Jun, J.C.; Rathore, A.; Younas, H.; Gilkes, D.; Polotsky, V.Y. Hypoxia-inducible factors and cancer. Curr. Sleep Med. Rep. 2017, 3, 1–10. [Google Scholar] [CrossRef] [Green Version]
- Qian, J.; Shen, S.; Chen, W.; Chen, N. Propofol reversed hypoxia-induced docetaxel resistance in prostate cancer cells by preventing epithelial-mesenchymal transition by inhibiting hypoxia-inducible factor 1alpha. Biomed. Res. Int. 2018, 2018, 4174232. [Google Scholar] [CrossRef] [Green Version]
- Erasalo, H.; Hamalainen, M.; Leppanen, T.; Maki-Opas, I.; Laavola, M.; Haavikko, R.; Yli-Kauhaluoma, J.; Moilanen, E. Natural stilbenoids have anti-inflammatory properties in vivo and down-regulate the production of inflammatory mediators NO, IL6, and MCP1 possibly in a PI3K/Akt-dependent manner. J. Nat. Prod. 2018, 81, 1131–1142. [Google Scholar] [CrossRef]
- Cimino, S.; Sortino, G.; Favilla, V.; Castelli, T.; Madonia, M.; Sansalone, S.; Russo, G.I.; Morgia, G. Polyphenols: Key issues involved in chemoprevention of prostate cancer. Oxid. Med. Cell Longev. 2012, 2012, 632959. [Google Scholar] [CrossRef]
- Zhou, Y.; Quan, G.; Wu, Q.; Zhang, X.; Niu, B.; Wu, B.; Huang, Y.; Pan, X.; Wu, C. Mesoporous silica nanoparticles for drug and gene delivery. Acta Pharm. Sin. B. 2018, 8, 165–177. [Google Scholar] [CrossRef]
- Chaudhary, Z.; Subramaniam, S.; Khan, G.M.; Abeer, M.M.; Qu, Z.; Janjua, T.; Kumeria, T.; Batra, J.; Popat, A. Encapsulation and controlled release of resveratrol within functionalized mesoporous silica nanoparticles for prostate cancer therapy. Front Bioeng. Biotechnol. 2019, 7, 225. [Google Scholar] [CrossRef]
- Kim, T.H.; Shin, Y.J.; Won, A.J.; Lee, B.M.; Choi, W.S.; Jung, J.H.; Chung, H.Y.; Kim, H.S. Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin. Biochim. Biophys. Acta 2014, 1840, 615–625. [Google Scholar] [CrossRef]
- Goldring, S.R.; Gravallese, E.M. Mechanisms of bone loss in inflammatory arthritis: Diagnosis and therapeutic implications. Arthritis Res. 2000, 2, 33–37. [Google Scholar] [CrossRef] [Green Version]
- Kamel, R.; Salama, A.H.; Mahmoud, A.A. Development and optimization of self-assembling nanosystem for intra-articular delivery of indomethacin. Int. J. Pharm. 2016, 515, 657–668. [Google Scholar] [CrossRef]
- Abbas, H.; Kamel, R.; El-Sayed, N. Dermal anti-oxidant, anti-inflammatory and anti-aging effects of Compritol ATO-based Resveratrol colloidal carriers prepared using mixed surfactants. Int. J. Pharm. 2018, 541, 37–47. [Google Scholar] [CrossRef]
- Kamel, R.; Abbas, H.; Shaffie, N.M. Development and evaluation of PLA-coated co-micellar nanosystem of Resveratrol for the intra-articular treatment of arthritis. Int. J. Pharm. 2019, 569, 118560. [Google Scholar] [CrossRef]
- Cheatham, B. GLUT4 and company: SNAREing roles in insulin-regulated glucose uptake. Trends Endocrinol. Metab. 2000, 11, 356–361. [Google Scholar] [CrossRef]
- American Diabetes, A. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010, 33, S62–S69. [Google Scholar] [CrossRef] [Green Version]
- Arab Sadeghabadi, Z.; Ziamajidi, N.; Abbasalipourkabir, R.; Mohseni, R. Garlic (Allium sativum) increases SIRT1 and SIRT2 gene expressions in the kidney and liver tissues of STZ- and STZ+niacinamide-induced diabetic rats. J. Basic Clin. Physiol. Pharmacol. 2018, 29, 463–467. [Google Scholar] [CrossRef]
- Gencoglu, H.; Tuzcu, M.; Hayirli, A.; Sahin, K. Protective effects of resveratrol against streptozotocin-induced diabetes in rats by modulation of visfatin/sirtuin-1 pathway and glucose transporters. Int. J. Food Sci. Nutr. 2015, 66, 314–320. [Google Scholar] [CrossRef]
- Mohseni, R.; ArabSadeghabadi, Z.; Ziamajidi, N.; Abbasalipourkabir, R.; RezaeiFarimani, A. Oral administration of resveratrol-loaded solid lipid nanoparticle improves insulin resistance through targeting expression of SNARE proteins in adipose and muscle tissue in rats with type 2 diabetes. Nanoscale Res. Lett. 2019, 14, 227. [Google Scholar] [CrossRef]
- Coradini, K.; Lima, F.O.; Oliveira, C.M.; Chaves, P.S.; Athayde, M.L.; Carvalho, L.M.; Beck, R.C. Co-encapsulation of resveratrol and curcumin in lipid-core nanocapsules improves their in vitro antioxidant effects. Eur. J. Pharm. Biopharm. 2014, 88, 178–185. [Google Scholar] [CrossRef]
- Oh, E.; Stull, N.D.; Mirmira, R.G.; Thurmond, D.C. Syntaxin 4 up-regulation increases efficiency of insulin release in pancreatic islets from humans with and without type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 2014, 99, E866–E870. [Google Scholar] [CrossRef] [Green Version]
- Amanat, S.; Taymouri, S.; Varshosaz, J.; Minaiyan, M.; Talebi, A. Carboxymethyl cellulose-based wafer enriched with resveratrol-loaded nanoparticles for enhanced wound healing. Drug Deliv. Transl. Res. 2020. [Google Scholar] [CrossRef] [PubMed]
- El-Mahrouk, G.M.; El-Gazayerly, O.N.; Aboelwafa, A.A.; Taha, M.S. Chitosan lactate wafer as a platform for the buccal delivery of tizanidine HCl: In vitro and in vivo performance. Int. J. Pharm. 2014, 467, 100–112. [Google Scholar] [CrossRef]
- Rezvanian, M.; Tan, C.K.; Ng, S.F. Simvastatin-loaded lyophilized wafers as a potential dressing for chronic wounds. Drug Dev. Ind. Pharm. 2016, 42, 2055–2062. [Google Scholar] [CrossRef] [PubMed]
- Yaman, I.; Derici, H.; Kara, C.; Kamer, E.; Diniz, G.; Ortac, R.; Sayin, O. Effects of resveratrol on incisional wound healing in rats. Surg. Today 2013, 43, 1433–1438. [Google Scholar] [CrossRef] [PubMed]
Properties | Size of the Particles and Encapsulation Efficiency of RES | Action of RES on the Target | Cellular Effect | Disease |
---|---|---|---|---|
Chitosan | 160.58 and 206.52 μm, 94.59% | Hippocampal region, MDA-MB cell line | Neuroprotective, anti-cancer | Alzheimer’s, colon cancer, diabetes |
Zinc-Pectinate | 950 um, 94% | Direct effect by pectinase for digestion in the colon | Colon-specific | Gastric complications |
Casein | 200 nm | Thromboxane A2 | Cardioprotective as anti-vasoconstrictor | Cardiac failure |
Polysorbate 80-coated poly(lactide) | 250 nm | Reducing the lipid peroxidation and TH loss in the MPTP-treatment | Antioxidant and the neuroprotective properties | Parkinson’s |
Zein | 300 nm | Reduction in the pro-inflammatory mediators | Anti-inflammatory | Endotoxic shock |
Transferrin (Tf)-modified polyethylene glycol-poly lactic acid (PEG-PLA) | 239.57 ± 2.53 nm | Toxic effects on glioma cells with tumor | In vitro cell cytotoxicity, anti-tumor activity, and cellular uptake | Glioma |
Gelucire 50/13 lipid matrix/HPβCD matrix | 329.9 ± 1.9 nm, 72.2 ± 1.5%. | ROS or free radicals in the lenses | Improvement in countering the oxidative stress by improving the SOD activity | Cataract |
Poly (lactic-co-glycolic) acid (PLGA) poly(-caprolactone)–poly(ethylene glycol) (PCL–PEG) nanoparticles | 200 nm (approx.) | Cochlear cells | Countering the generation of ROS due to cisplatin | Hearing loss |
Silk fibroin | 250 nm (approx.) | Epithelium of the mouth | Decreasing the levels of IL-1beta and IL-6 | Periodontitis |
polymeric micelles with polycaprolactone (PCL)-polyethyleneglycol (PEG) | 83.47 ± 0.44 nm | Crossing the blood-brain barrier | ROS generated by the amyloid-beta peptide, caspase-3 reduction | Neurodegenerative disease of Alzheimer’s and Parkinson’s |
Oat protein-shellac complex nanoparticles | 323 nm, 60–90% | Anti-oxidant mechanism | Scavenging hydroxyl radicals | Liver |
Gold nanoparticles | 10 nm | Reducing the phosphorylation of extracellular signal-regulated kinase (ERK) 1/2 and NF-KP phosphorylation | IL-1beta, IL-6, and TNF-alpha, Vascular Cell Adhesion Molecule 1 (VCAM-1), Intercellular Adhesion Molecule-1 (ICAM-1) and Monocyte Chemoattractant Protein-1 (MCP-1) | Diabetic retinopathy |
Mesoporous Carbon nanoparticles | 187 nm | Caspase 3 activation, scavenging ROS in PC3 cells | Cytotoxic effect, anti-oxidative | Triple-negative breast cancer (TNBC), prostate cancer |
Poly(ethylene oxide)–poly(propylene oxide) PEO-PPO block copolymers | 10–100 nm | Reduction in TNF-alpha | Anti-inflammation, tissue swelling and synovial inflammation | Arthritis |
Solid lipids | 248 nm | Snap23, Stx4, and Vamp2 have increased | Improved insulin resistance | Insulin resistance in type II diabetes |
Cellulose acetate butyrate (CAB), and carboxymethylcellulose | wafers, 87–92% | Necrosis of the tissue | Increase in collagen | Wound dressing and healing |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Chung, I.-M.; Subramanian, U.; Thirupathi, P.; Venkidasamy, B.; Samynathan, R.; Gangadhar, B.H.; Rajakumar, G.; Thiruvengadam, M. Resveratrol Nanoparticles: A Promising Therapeutic Advancement over Native Resveratrol. Processes 2020, 8, 458. https://doi.org/10.3390/pr8040458
Chung I-M, Subramanian U, Thirupathi P, Venkidasamy B, Samynathan R, Gangadhar BH, Rajakumar G, Thiruvengadam M. Resveratrol Nanoparticles: A Promising Therapeutic Advancement over Native Resveratrol. Processes. 2020; 8(4):458. https://doi.org/10.3390/pr8040458
Chicago/Turabian StyleChung, Ill-Min, Umadevi Subramanian, Prabhu Thirupathi, Baskar Venkidasamy, Ramkumar Samynathan, Baniekal Hiremath Gangadhar, Govindasamy Rajakumar, and Muthu Thiruvengadam. 2020. "Resveratrol Nanoparticles: A Promising Therapeutic Advancement over Native Resveratrol" Processes 8, no. 4: 458. https://doi.org/10.3390/pr8040458